



Company Profile

RedHill Biopharma, established in 2009, is a publicly traded (NASDAQ / TASE: RDHL) specialty biopharmaceutical company, headquartered in Israel, primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases, including cancer.

RedHill's pipeline currently includes drugs in advanced clinical development stages addressing clear medical needs and aiming to relieve suffering and save lives. RedHill's drugs are largely de-risked and are potentially of lower cost and faster to market than new chemical entities under development.


RedHill's products are based on several technology platforms and address several disease targets, thus providing for risk diversification.

RedHill's experienced management team, board of directors and advisory board, based in Israel, the US, Canada and Europe, comes with a successful track record of bringing patented drugs to the market, as well as extensive managerial, financial, and transactional expertise.

Stock Performance


NASDAQ: RDHL.US ¹

Last Trade:	9.08
Trade Time:	3:59 PM ET Jun 23, 2017
Change:	0.12 ↑ (1.339%)
Volume	53,288



TASE: RDHL ¹

Last Trade:	315.70
Trade Time:	3:24 PM IT Jun 25, 2017
Change:	0.00 (0.000%)
Volume	120,720



Press Releases [\[View all \]](#)

Jun 19, 2017

[RedHill Biopharma to Host Conference Call on Successful Phase III Top-Line Results with BEKINDA® for Acute Gastroenteritis](#)

Jun 15, 2017

[RedHill Biopharma Announces Confirmatory Phase III Study Initiated with RHB-105 \(TALICIA™\) for H. pylori Infection](#)

Jun 15, 2017

[RedHill Biopharma Announces Confirmatory Phase III Study Initiated with RHB-105 \(TALICIA\(TM\)\) for H. pylori Infection](#)

Events [\[View all \]](#)

Sep 10–12, 2017

[Rodman & Renshaw 19th Annual Global Investment Conference](#)

Sep 26–27, 2017

[BioPharm America 2017](#)

Financials [\[View all \]](#)

[First Quarter Financial Results](#)

Feb 23, 2017

[Annual Report for Foreign Private Issuers \(20-F\)](#)

RedHill Biopharma Ltd

Investor Relations Department
21 Haabaa St
Tel Aviv 64739
Israel

[Visit IR website](#) [↗](#)

[Sign-up for email alerts](#) [↗](#)

